Dokucu Mehmet E
Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences 710 North Lake Shore Drive #1324, Chicago, Illinois 60611,.
Curr Treat Options Psychiatry. 2015 Sep;2(3):339-348. doi: 10.1007/s40501-015-0055-4. Epub 2015 Jul 3.
Schizophrenia is a psychiatric disorder that causes great suffering and debilitation worldwide. We have a multitude of medications that are effective for psychosis. However, these have not been successful in treating the negative and cognitive symptom domains of schizophrenia. These symptoms are responsible for the larger part of functional impairments that result from schizophrenia. In addition, there are many patients for whom no significant improvement is achieved even in the positive symptom domain. Hence, other treatment modalities have been explored to help these patients. Electroconvulsive therapy and transcranial magnetic stimulation are two of the most promising adjunct treatment methods for medication resistant schizophrenia. Electroconvulsive therapy is the gold standard treatment for catatonias whether associated with schizophrenia, mood disorders or other non-psychiatric disorders. Although not effective for negative symptoms, electroconvulsive therapy provides substantial augmentation to antipsychotic medications in improving positive symptoms and overall severity. Electroconvulsive therapy should be considered more often in patients with inadequate response to antipsychotic medications even when they do not have prominent affective symptoms. Transcranial magnetic stimulation has emerged as a promising useful therapeutic tool in targeting medication resistant auditory hallucinations and negative symptoms. Transcranial magnetic stimulation has proven to be very safe and well-tolerated by the patients in spite of its labor intensiveness. The incorporation of transcranial magnetic stimulation to routine clinical use awaits further studies to substantiate its efficacy and to optimize and customize treatment parameters to individual patients and their symptom patterns. Moreover, combining transcranial magnetic stimulation with electroconvulsive therapy to synergize their likely different mechanisms of action is another exciting possibility.
精神分裂症是一种在全球范围内造成巨大痛苦和功能衰退的精神障碍。我们有多种对精神病有效的药物。然而,这些药物在治疗精神分裂症的阴性和认知症状方面并未取得成功。这些症状是精神分裂症导致功能障碍的主要原因。此外,还有许多患者即使在阳性症状方面也没有显著改善。因此,人们探索了其他治疗方式来帮助这些患者。电休克疗法和经颅磁刺激是治疗药物难治性精神分裂症最有前景的两种辅助治疗方法。电休克疗法是治疗紧张症的金标准,无论其是否与精神分裂症、情绪障碍或其他非精神疾病相关。尽管电休克疗法对阴性症状无效,但在改善阳性症状和总体严重程度方面,它能显著增强抗精神病药物的疗效。即使患者没有明显的情感症状,对于对抗精神病药物反应不足的患者,也应更频繁地考虑使用电休克疗法。经颅磁刺激已成为一种有前景的有用治疗工具,可针对药物难治性幻听和阴性症状。尽管经颅磁刺激操作繁琐,但已被证明非常安全且患者耐受性良好。将经颅磁刺激纳入常规临床应用有待进一步研究,以证实其疗效,并根据个体患者及其症状模式优化和定制治疗参数。此外,将经颅磁刺激与电休克疗法相结合,以协同它们可能不同的作用机制,是另一种令人兴奋的可能性。